UroToday - Docetaxel Plus Prednisone Versus Mitoxantrone Plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center - Abstract

[Guest guest]

http://www.urotoday.com/browse_categories/prostate_cancer/docetaxel_plus_prednisone_versus_mitoxantrone_plus_prednisone_for_metastatic_hormonerefractory_prostate_cancer_in_chinese_patients_experience_of_a_single_center__abstract.html

Friday, 04 January 2008

Department

of Urology, Cancer Hospital, Fudan

University, Shanghai, PR China

To

preliminarily investigate the efficacy of docetaxel plus prednisone and

mitoxantrone plus prednisone for treating metastatic hormone-refractory prostate

cancer and to further evaluate its adverse events in Chinese patients.

83

patients with metastatic hormone-refractory prostate cancer were enrolled in

the trial and given a combination of docetaxel 75 mg/m(2) intravenously on day

2 or mitoxantrone 12 mg/m(2) on day 1 plus prednisone 5 mg twice daily on days

1-21, 21 days a cycle. Serum PSA level, relief of bone pain, myelosuppression,

and vomiting were recorded and calculated

Docetaxel

plus prednisone was administered to 44 patients: 13.6% (6/44) of them achieved

complete response, 29.5% (13/44) partial response, 29.5% (13/44) had stable

disease, and 27.3% (12/44) had disease progression. The average time to PSA

progression was 37.8 weeks (12-101 weeks) in the response and stable disease

patients. The 12 patients with disease progression were given MP as salvage

therapy, and 16.7% (2/12) achieved a partial response, 25.0% (3/12) had stable

disease and formed the new baseline. Only 2 patients died of disease

aggravation. Mitoxantrone plus prednisone were given to 39 patients, and 7.7%

(3/39) of them achieved complete response, 25.6% (10/39) partial response,

25.6% (10/39) had a stable disease, and 41.0% (16/39) of patients had disease

progression. The mean time to PSA progression was 25.3 weeks (8-61 weeks) in

the response and stable disease patients. The 14 patients with disease

progression were administered DP as a salvage therapy and 7.1% (1/14) achieved

complete response, 35.7% (5/14) partial response, and 21.4% (3/14) had stable

disease and formed the new baseline. Four patients had died at the last

follow-up.

In

Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus

prednisone in PSA response rate and PSA control, but has a bit more toxicity.

When the tumor is resistant to one regimen, the other might still be effective

in controlling disease progression. © 2007 S. Karger AG, Basel.

Written

by

Zhang HL, Ye DW, Yao

XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.

Reference

Urol

Int. 2007;79(4):307-11

doi:10.1159/000109714

PubMed

Abstract

PMID:18025847